Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.
The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...
HER2, showing improved event-free and overall survival in lung metastatic osteosarcoma. The start-up, which joined JLABS and ...
Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...
Breast Cancer Diagnostic And Drug Technologies Market Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
According to a recent report from Future Market Insights, the global allogeneic T-cell therapies market was valued at USD 1.1 ...
Bruce Cozadd, the retiring CEO of Jazz Pharmaceuticals, has outlined a developing oncology pipeline at the company. Speaking ...
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback